Molecular profiling identifies distinct subtypes across TP53 mutant tumors
Cited by 9
Related Papers
Exogenous IGFBP-2 promotes proliferation, invasion, and chemoresistance to temozolomide in glioma cells via the integrin β1-ERK pathway
|British Journal of Cancer|2014|108
Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth
|Journal for ImmunoTherapy of Cancer|2020|73
<p>IFI30 Is a Novel Immune-Related Target with Predicting Value of Prognosis and Treatment Response in Glioblastoma</p>
|OncoTargets and Therapy|2020|53
Lithium enhances the antitumour effect of temozolomide against TP53 wild-type glioblastoma cells via NFAT1/FasL signalling
|British Journal of Cancer|2017|30